Your Expert

Your Expert

Yourgene have worked closely with Key Opinion Leaders, high profile partners, customers and market renowned experts within their chosen fields to develop a series of Your Expert papers. We aim to cover a range of different topics and content relevant to the portfolio of applications that Yourgene operates in. We hope these papers serve as relevant, informative and educational resources.

The Truth About Statistics in NIPT

Non-invasive prenatal testing (NIPT) is a relatively new tool in prenatal care, helping clinicians to assess the chance of fetal chromosomal abnormalities early in a pregnancy. It is more accurate than traditional screening techniques for common fetal aneuploidies – Down’s syndrome, Patau’s syndrome, and Edwards’ syndrome – and carries no associated miscarriage risk.

A true Manchester partnership advancing precision medicine

Yourgene spoke with Joely Irlam-Jones, a Research Associate at the University of Manchester and Director and CEO of ManTRa Diagnostics, a spin-out company from the University of Manchester that is developing patient stratification solutions to personalise medicine and improve cancer treatment outcomes. The team have developed tumour-site-specific gene expression signatures which indicate the oxygen status of the tumour. ManTRa and the Yourgene Genomic Services team have a longstanding history of over 10 years working together on this development.

NIPT screening: Ticking all the boxes

Future Health is the UK’s largest Stem Cell Bank with over 20 years of history and experience. They have 2 storage facilities, one in the UK and one in Switzerland and a physical presence in over 40 countries worldwide. Future Health do not just offer stem cell banking, their services include screening, both NIPT and newborn screening.

A private Provider’s view on NIPT

Non-invasive prenatal screening (NIPT) is available in the form of the IONA® test and IONA® Care from Yourgene Health’s Genomic Services laboratory in Manchester, UK. The test requires a maternal blood sample from the 10th week of gestation and uses next generation sequencing to determine the likelihood that the pregnancy is affected by trisomy 21, 18 or 13.

Alzheimer’s disease and polygenic risk score

Yourgene’s Director of Marketing, Jo Cross, interviewed Dr Richard Pither, CEO of Cytox about genoSCORE™-LAB – a polygenic risk score test for understanding a patient’s risk of developing Alzheimer’s disease. Yourgene Genomic Services run the genoSCORE™-LAB test in their Manchester laboratory.

LightBench®: Enabling liquid biopsies for cancer detection

A Yourgene Health LightBench® customer, Dr Hunter Underhill is an Assistant Professor of Paediatrics within the medical genetics’ division at the University of Utah School of Medicine. He has a research lab at the Huntsman Cancer Institute studying the applicability of cfDNA detection for brain tumour surveillance and monitoring.

1 2 3